AbdulGhani_Q8_Layout 1 27/08/2009 16:17 Page 23
Mitochondrial Dysfunction in Type 2 Diabetes – An Update
1. DeFronzo RA, Banting Lecture. From the Triumvirate to the kinase activity in muscle, J Biol Chem, 2002;277:50230–36. 44. De Feyter HM, et al., Early or advanced stage type 2
Ominous Octet: A new paradigm for the treatment of type 23. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA, diabetes is not accompanied by in vivo skeletal muscle
2 diabetes, Diabetes, 2008; in press. Rosiglitazone improves downstream insulin-receptor mitochondrial dysfunction, Eur J Endocrinol, 2008;158:
2. Reaven GM, Banting lecture. Role of insulin resistance in signaling in type 2 diabetic patients, Diabetes, 2003;52: 643–53.
human disease, Diabetes, 1988;37:1595–1607. 1943–50. 45. Ritov VB, Menshikova EV, He J, et al., Deficiency of
3. Bajaj M, Defronzo RA, Metabolic and molecular basis of 24. Pendergrass M, Bertoldo A, Bonadonna R, et al., Muscle subsarcolemmal mitochondria in obesity and type 2
insulin resistance, J Nucl Cardiol, 2003;10:311–23. glucose transport and phosphorylation in type 2 diabetic, diabetes, Diabetes, 2005;54:8–14.
4. Cusi K, Maezono K, Osman A, et al., Insulin resistance obese non-diabetic, and genetically predisposed 46. Rolo AP, Palmeira CM, Diabetes and mitochondrial
differentially affects the PI 3-kinase-and MAP kinase- individuals, Am J Physiol Endocrinol Metab, 2007;292:E92–100. function: role of hyperglycemia and oxidative stress,
mediated signaling in human muscle, J Clin Invest, 25. Thompson AL, Cooney GJ, Acyl-CoA inhibition of Toxicol Appl Pharmacol, 2006;212:167–78.
2000;105:311–20. hexokinase in rat and human skeletal muscle is a 47. Boushel R, Gnaiger E, Schjerling P, et al., Patients with type
5. DeFronzo RA, Pathogenesis of type 2 diabetes mellitus: potential mechanism of lipid-induced insulin resistance, 2 diabetes have normal mitochondrial function in skeletal
metabolic and molecular implications for identifying Diabetes, 2000;49:1761–4. muscle, Diabetologia, 2007;50:790–96.
diabetes genes, Diabetes Rev, 1007;5:117–69. 26. Tippett PS, Neet KE, An allosteric model for the inhibition 48. Asmann YW, Stump CS, Short KR, et al., Skeletal muscle
6. Suzuki R, Tobe K, Aoyama M, et al., Both insulin signaling of glucokinase by long chain acyl coenzyme A, J Biol Chem, mitochondrial functions, mitochondrial DNA copy
defects in the liver and obesity contribute to insulin 1982; 257:14846–52. numbers, and gene transcript profiles in type 2 diabetic
resistance and cause diabetes in Irs2(-/-. mice, J Biol Chem, 27. Rothman DL, Magnusson I, Cline G, et al., Decreased and nondiabetic subjects at equal levels of low or high
2004;279:25039–49. muscle glucose transport/phosphorylation is an early insulin and euglycemia, Diabetes, 2006;55:3309–19.
7. Groop LC, et al., Glucose and free fatty acid metabolism in defect in the pathogenesis of non-insulin-dependent 49. Patti ME, Butte AJ, Crunkhorn S, et al., Coordinated
non-insulin-dependent diabetes mellitus. Evidence for diabetes mellitus, Proc Natl Acad Sci U S A, 1995;92:983–7. reduction of genes of oxidative metabolism in humans
multiple sites of insulin resistance, J Clin Invest, 1989; 28. Wititsuwannakul D, Kim K, Mechanism of palmityl with insulin resistance and diabetes: Potential role of
84:205–13. coenzyme A inhibition of liver glycogen synthase, PGC1 and NRF1, Proc Natl Acad Sci U S A, 2003;100:
8. Groop LC, Saloranta C, Shank M, et al., The role of free J Biol Chem, 1977;252: 7812–17. 8466–71.
fatty acid metabolism in the pathogenesis of insulin 29. Randle PF, Garland PB, Hales CN, Newsholme EA, The 50. Mootha VK, Lindren CM, Eriksson KF, et al., PGC-1 alpha-
resistance in obesity and noninsulin-dependent diabetes glucose fatty acid cycle: its role in insulin sensitivity and responsive genes involved in oxidative phosphorylation
mellitus, J Clin Endocrinol Metab, 1991;72:96–107. the metabolic disturbances of diabetes mellitus, Lancet, are coordinately downregulated in human diabetes, Nature
9. Bays H, et al., Role of the adipocyte, free fatty acids, and 1963;1:785–9. Gen, 2003;34:267–73.
ectopic fat in pathogenesis of type 2 diabetes mellitus: 30. Kelley D, Mandarino L, Fuel selection in human skeletal 51. Mogensen M, Sahlin K, Fernstrom M, et al., Mitochondrial
peroxisomal proliferator-activated receptor agonists muscle in insulin resistance: a reexamination, Diabetes, respiration is decreased in skeletal muscle of patients
provide a rational therapeutic approach, J Clin Endocrinol 2000;49:677–83. with type 2 diabetes, Diabetes, 2007;56:159–9.
Metab, 2004;89:463–78. 31. Kelley DE, Simoneau JA, Impaired free fatty acid utilization 52. Kelley DE, He J, Menshikova EV, Ritov VB, Dysfunction of
10. Belfort R, Harrison SA, Brown K, et al., A placebo by skeletal muscle in non-insulin-dependent diabetes mitochondria in human skeletal muscle in type 2
controlled trial of pioglitazone in patients with non- mellitus, J Clin Invest, 1994;94:2349–56. diabetes, Diabetes, 2002;51:2944–50.
alcoholic steatohepatitis, N Engl J Med, 2006;355:2297–2307. 32. Cha BS, Ciaraldi TP, Park KS, et al., Impaired fatty acid 53. Toledo FG, Watkins S, Kelley DE, Changes induced by
11. Bajaj M, Suraamornkul S, Romanelli A, et al., Effect of metabolism in type 2 diabetic skeletal muscle cells is physical activity and weight loss in the morphology of
sustained reduction in plasma free fatty acid reversed by PPARgamma agonists, Am J Physiol Endocrinol intermyofibrillar mitochondria in obese men and women,
concentration on intramuscular long chain-fatty acyl-CoAs Metab, 2005;289:E151–E159. J Clin Endocrinol Metab, 2006;91:3224–7.
and insulin action in patients with type 2 diabetes, 33. Thyfault JP, Kraus RM, Hickner RC, et al., Impaired plasma 54. Abdul-Ghani MA, Jani R, Chavez A, et al., Mitochondrial
Diabetes, 2005;54:3148–53. fatty acid oxidation in extremely obese women, Am J reactive oxygen species generation in obese non-diabetic
12. Mayerson AB, Hundal RS, Dufour S, et al., The effects of Physiol Endocrinol Metab, 2004;287:E1076–E81. and T2DM subjects, Diabetologia, 2009; in press.
rosiglitazone on insulin sensitivity, lipolysis, and hepatic 34. Kim JY, Hickner RC, Cortright RL, et al., Lipid oxidation is 55. Richardson DK, Kashyap S, Bajaj M, et al., Lipid infusion
and skeletal muscle triglyceride content in patients with reduced in obese human skeletal muscle, Am J Physiol induces an inflammatory/fibrotic response and
type 2 diabetes, Diabetes, 2002;51:797–802. Endocrinol Metab, 2000;279:E1039–E1044. decreases expression of nuclear encoded mitochondrial
13. Sharma S, Adrogue JV, Golfman L, et al., Intramyocardial 35. Szendroedi J, Schmid AI, Chmelik M, et al., Muscle genes in human skeletal muscle, J Biol Chem, 2005;280:
lipid accumulation in the failing human heart resembles mitochondrial ATP synthesis and glucose 10290–97.
the liptoxic rat heart, FASEB, 2004;18:692–700. transport/phosphorylation in type 2 diabetes, PLoS Med, 56. Abdul-Ghani MA, Muller F, Liu Y, et al., Deleterious effect
14. Kim JK, Fillmore JJ, Chen Y, et al., Tissue-specific 2007;4:0858–0867. of elevated fatty acid metabolites concentration on
overexpression of lipoprotein lipase causes tissue-specific 36. Petersen KF, Dufour S, et al., Decreased insulin-stimulated skeletal muscle mitochondrial ATP synthesis, Am J Physiol
insulin resistance, Proc Natl Acad Sci U S A, 2001;98:7522–7. ATP synthesis and phosphate transport in muscle of Endocrinol Metab, 2008;295:E678–85.
15. Houmard JA, Tanner CJ, Yu C, et al., Effect of weight loss insulin-resistant offspring of type 2 diabetic parents, PLoS 57. Benton CR, Nickerson JG, Lally J, et al., Modest PGC-1alpha
on insulin sensitivity and intramuscular long-chain fatty Med, 3005; 2:e233. overexpression in muscle in vivo is sufficient to increase
acyl-CoAs in morbidly obese subjects, Diabetes, 37. Scheuermann-Freestone M, Madsen PL, Manners D, et al., insulin sensitivity and palmitate oxidation in SS, not IMF,
2002;51:2959–63. Abnormal cardiac and skeletal muscle energy metabolism mitochondria, J Biol Chem, 2008;283(7):4228–40.
16. Ellis BA, et al., Long-chain acyl-CoA esters as indicators of in patients with type 2 diabetes, Circulation, 2003;107: 58. Lagouge M, Argmann C, et al., Resveratrol improves
lipid metabolism and insulin sensitivity in rat and human 3040–46. mitochondrial function and protects against metabolic
muscle, Am J Physiol Endocrinol Metab, 2000;279:E554–60. 38. Petersen KF, et al., Mitochondrial dysfunction in the disease by activating SIRT1 and PGC-1alpha, Cell,
17. Itani SI, Ruderman NB, et al., Lipid-induced insulin elderly: possible role in insulin resistance, Science, 2003; 2006;127: 1109–22.
resistance in human muscle is associated with changes in 300:1140–42. 59. Pospisilik JA, Knauf C, Joza N, et al., Targeted deletion of
diacylglycerol, protein kinase C, and IB-, Diabetes, 2002;51: 39. Petersen KF, Dufour S, Befroy D, et al., Impaired AIF decreases mitochondrial oxidative phosphorylation
2005–11. mitochondrial activity in the insulin-resistant offspring of and protects from obesity and diabetes, Cell,
18. Adams JM II, Pratipanawatr T, Berria R, et al., Ceramide patients with type 2 diabetes, N Engl J Med, 2007;131:476–91.
content is increased in skeletal muscle from obese 2004;350:664–71. 60. Calvo JA, Daniels TG, Wang X, et al., Muscle-specific
insulin-resistant humans, Diabetes, 2004;53:25–31. 40. Brehm A, Krssak M, Schmid AI, et al., Increased lipid expression of PPARg coactivator-1a improves exercise
19. Morino K, Petersen KF, Dufour S, et al., Reduced availability impairs insulin-stimulated ATP synthesis in performance and increases peak oxygen uptake, J Appl
mitochondrial density and increased IRS-1 serine human skeletal muscle, Diabetes, 2006;55:136–40. Physiol, 2008;104:1304–12.
phosphorylation in muscle of insulin-resistant offspring 41. Befroy DE, Petersen KF, Dufour S, et al., Impaired 61. Menshikova EV, Ritov VB, Toledo FG, et al., Effects of
of type 2 diabetic parents, J Clin Invest, 2005;115: mitochondrial substrate oxidation in muscle of insulin- weight loss and physical activity on skeletal muscle
3587–93. resistant offspring of type 2 diabetic patients, Diabetes, mitochondrial function in obesity, Am J Physiol Endocrinol
20. Griffin ME, Marcucci MJ, Cline GW, et al., Free fatty acid- 2007;56:1376–81. Metab, 2005;288:E818–25.
induced insulin resistance is associated with activation of 42. Schrauwen-Hinderling VB, Kooi ME, Hesselink MK, et al., 62. Toledo FG, Menshikova EV, Azuma K, et al.,
protein kinase C theta and alterations in the insulin Impaired in vivo mitochondrial function but similar Mitochondrial capacity in skeletal muscle is not
signaling cascade, Diabetes, 1999;48:1270–74. intramyocellular lipid content in patients with type 2 stimulated by weight loss despite increases in insulin
21. Dresner A, Laurent D, Marcucci M, et al., Effects of free diabetes mellitus and BMI-matched control subjects, action and decreases in intramyocellular lipid content,
fatty acids on glucose transport and IRS-1-associated Diabetologia, 2007;50:113–20. Diabetes, 2008;57:987–94.
phosphatidylinositol 3-kinase activity, J Clin Invest, 43. Phielix E, Schrauwen-Hinderling VB, Mensink M, et al., 63. Schrauwen-Hinderling VB, et al., The insulin sensitizing
1999;103:253–9. Lower intrinsic ADP-stimulated mitochondrial respiration effect of rosiglitazone in type 2 diabetes mellitus
22. Yu C, Chen Y, Cline GW, et al., Mechanism by which fatty underlies in vivo mitochondrial dysfunction in muscle of patients does not require improved in vivo muscle
acids inhibit insulin activation of insulin receptor male type 2 diabetic patients, Diabetes, 2008;57(11): mitochondrial function, J Clin Endocrinol Metab, 2008;93:
substrate-1 (IRS-1)-associated phosphatidylinositol 3- 2943–9. 2917–21.
EUROPEAN ENDOCRINOLOGY 23
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87